The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

Paolo A. Ascierto; Lisa H. Butterfield; Sandra Demaria; Robert L. Ferris; Gordon J. Freeman; Roger S. Lo; Alberto Mantovani; Paul Nathan; Omid Hamid; Katerina Politi; Igor Puzanov

doi:10.1186/s40425-019-0683-0

The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

Paolo A. Ascierto
, Lisa H. Butterfield
, Sandra Demaria
, Robert L. Ferris
, Gordon J. Freeman
, Roger S. Lo
, Alberto Mantovani
, Paul Nathan
, Omid Hamid
, Katerina Politi
, Igor Puzanov

Medicine

IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
University of California at San Francisco
Cornell University
University of Pittsburgh
Harvard University
University of California at Los Angeles
Humanitas University
Queen Mary University of London
East and North Hertfordshire NHS Trust
The Angeles Clinic and Research Institute
Yale University

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

Original language	English
Article number	221
Journal	Journal for ImmunoTherapy of Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0683-0
State	Published - Aug 15 2019

Keywords

Anti-CTLA-4
Anti-PD-1
Cancer
Combination therapy
Immunity
Immunotherapy
Treatment resistance

Access to Document

10.1186/s40425-019-0683-0

Cite this

@article{b5f096a0817f4d85b1cc36a3c626ffe5,

title = "The great debate at {"}immunotherapy Bridge 2018{"}, Naples, November 29th, 2018",

abstract = "As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.",

keywords = "Anti-CTLA-4, Anti-PD-1, Cancer, Combination therapy, Immunity, Immunotherapy, Treatment resistance",

author = "Ascierto, \{Paolo A.\} and Butterfield, \{Lisa H.\} and Sandra Demaria and Ferris, \{Robert L.\} and Freeman, \{Gordon J.\} and Lo, \{Roger S.\} and Alberto Mantovani and Paul Nathan and Omid Hamid and Katerina Politi and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = aug,

day = "15",

doi = "10.1186/s40425-019-0683-0",

language = "English",

volume = "7",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

AU - Ascierto, Paolo A.

AU - Butterfield, Lisa H.

AU - Demaria, Sandra

AU - Ferris, Robert L.

AU - Freeman, Gordon J.

AU - Lo, Roger S.

AU - Mantovani, Alberto

AU - Nathan, Paul

AU - Hamid, Omid

AU - Politi, Katerina

AU - Puzanov, Igor

PY - 2019/8/15

Y1 - 2019/8/15

N2 - As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

AB - As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - Cancer

KW - Combination therapy

KW - Immunity

KW - Immunotherapy

KW - Treatment resistance

UR - https://www.scopus.com/pages/publications/85070958115

U2 - 10.1186/s40425-019-0683-0

DO - 10.1186/s40425-019-0683-0

M3 - Review article

C2 - 31416487

AN - SCOPUS:85070958115

SN - 2051-1426

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 1

M1 - 221

ER -

The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this